[Effect of meproscillarin on left ventricular hemodynamics (author's transl)].
In 10 patients with angiographically proven coronary artery disease we investigated the influence of the glycoside 14-hydroxy-3beta-[(4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (meproscillarin, Clift) on left ventricular performance with invasive methods. After a single i.v. bolus injection a decrease in left ventricular end-diastolic pressure associated with an increase of the maximum rate of pressure rise (dp/dtmax) and left ventricular pressure (LVP) was observed. These changes were not accompanied by significant alterations of the heart rate during an observation period of 60 min.
D002301:Cardiac Glycosides / Q000494:pharmacology*; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D010919:Placebos; D011312:Pressure; D013997:Time Factors
D002301:Cardiac Glycosides; D010919:Placebos
Die Wirkung von Meproscillarin auf die Hämodynamik des linken Ventrikels.